Hematology Advisor asked Prithviraj Bose, MD, to discuss the latest research on treatment options for CLL presented at the ASH 2018 Annual Meeting.
Research presented at the 2018 ASH Annual Meeting provided insights into the role of factor VIII as a therapeutic agent for severe hemophilia A.
Researchers analyzed 1110 patients who had received transplanted grafts from HLA-matched and mismatched relatives and unrelated donors.
Allogeneic hematopoietic cell transplantation was tolerated well by pediatric patients with sickle cell disease and transfusion-dependent thalassemia.
Results from a study in which patients with Fanconi anemia underwent a reduced intensity conditioning regimen followed by bone marrow transplantation.
Eltrombopag plus IST was compared with IST alone in a simulated population of 1 million patients with severe aplastic anemia.
The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.
The drug’s ability to boost late-stage erythropoiesis makes it a potential treatment option for patients with beta-thalassemia.
A personalized prediction model for probability of survival in patients with MDS who undergo HCT is presented at the ASH 2018 Annual Meeting.
The efficacy, safety, and feasibility of using hydroxyurea as a therapeutic agent for sickle cell anemia have not been assessed in many populations.
Researchers probed mutant calreticulins to determine whether they were secreted and behaved extracellularly as cytokines.
Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo
Stringent CR criteria may not predict clinical outcomes for patients with MM.
Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.
The need for dose reductions did not significantly affect progression-free survival in patients with WM treated with ibrutinib.